Literature DB >> 12569551

The product of the candidate prostate cancer susceptibility gene ELAC2 interacts with the gamma-tubulin complex.

Wouter Korver1, Claudia Guevara, Yang Chen, Saskia Neuteboom, Rob Bookstein, Sean Tavtigian, Emma Lees.   

Abstract

ELAC2 is a novel candidate cancer susceptibility gene located on chromosome 17p: Carriers of mutations in ELAC2 display a higher risk of developing prostate cancer. Overexpression of ELAC2 in tumor cells causes a delay in G2-M progression characterized by accumulation of cyclin B levels. Consistent with a function in mitosis, further biochemical analysis revealed that ELAC2 physically interacts with the gamma-tubulin complex. This is the first biologic insight into the function of this new putative cancer susceptibility gene, providing clues of how perturbation of ELAC2 might promote tumorigenesis through irregular cell division. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12569551     DOI: 10.1002/ijc.10945

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  24 in total

1.  The N-terminal half-domain of the long form of tRNase Z is required for the RNase 65 activity.

Authors:  Hiroaki Takaku; Asako Minagawa; Masamichi Takagi; Masayuki Nashimoto
Journal:  Nucleic Acids Res       Date:  2004-08-18       Impact factor: 16.971

Review 2.  Mitochondrial tRNA 3' end metabolism and human disease.

Authors:  Louis Levinger; Mario Mörl; Catherine Florentz
Journal:  Nucleic Acids Res       Date:  2004-10-11       Impact factor: 16.971

3.  Effect of changes in the flexible arm on tRNase Z processing kinetics.

Authors:  Louis Levinger; Angela Hopkinson; Rohini Desetty; Christopher Wilson
Journal:  J Biol Chem       Date:  2009-04-07       Impact factor: 5.157

4.  A novel class of small RNAs: tRNA-derived RNA fragments (tRFs).

Authors:  Yong Sun Lee; Yoshiyuki Shibata; Ankit Malhotra; Anindya Dutta
Journal:  Genes Dev       Date:  2009-11-15       Impact factor: 11.361

5.  17p12 deletion in breast cancer predicts resistance to neoadjuvant chemotherapy.

Authors:  Wonshik Han; Jung Hoon Woo; Yoon Kyung Jeon; Song-Ju Yang; Jihyoung Cho; Eunyoung Ko; Tae-You Kim; Seock-Ah Im; DO-Youn Oh; In-Ae Park; Ki-Tae Hwang; Hyeong-Gon Moon; Kap-Seok Yang; Dong-Young Noh
Journal:  Exp Ther Med       Date:  2011-06-29       Impact factor: 2.447

6.  Genome-wide association study of myelosuppression in non-small-cell lung cancer patients with platinum-based chemotherapy.

Authors:  S Cao; S Wang; H Ma; S Tang; C Sun; J Dai; C Wang; Y Shu; L Xu; R Yin; X Song; H Chen; B Han; Q Li; J Wu; C Bai; J Chen; G Jin; Z Hu; D Lu; H Shen
Journal:  Pharmacogenomics J       Date:  2015-03-31       Impact factor: 3.550

7.  ELAC2 polymorphisms and prostate cancer risk: a meta-analysis based on 18 case-control studies.

Authors:  B Xu; N Tong; J-m Li; Z-d Zhang; H-f Wu
Journal:  Prostate Cancer Prostatic Dis       Date:  2010-03-16       Impact factor: 5.554

8.  Developmental roles of Drosophila tRNA processing endonuclease RNase ZL as revealed with a conditional rescue system.

Authors:  Xie Xie; Veronica Dubrovskaya; Nancy Yacoub; Joanna Walska; Tara Gleason; Katherine Reid; Edward B Dubrovsky
Journal:  Dev Biol       Date:  2013-07-15       Impact factor: 3.582

9.  Drosophila RNase Z processes mitochondrial and nuclear pre-tRNA 3' ends in vivo.

Authors:  Edward B Dubrovsky; Veronica A Dubrovskaya; Louis Levinger; Steffen Schiffer; Anita Marchfelder
Journal:  Nucleic Acids Res       Date:  2004-01-09       Impact factor: 16.971

Review 10.  Genetic susceptibility to prostate cancer in men of African descent: implications for global disparities in incidence and outcomes.

Authors:  Charnita M Zeigler-Johnson; Elaine Spangler; Mohamed Jalloh; Serigne M Gueye; Hanna Rennert; Timothy R Rebbeck
Journal:  Can J Urol       Date:  2008-02       Impact factor: 1.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.